The role of Factor Inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme

Enfeng Wang, Chunyang Zhang, Navatha Polavaram, Fengming Liu, Gang Wu, Mark A. Schroeder, Julie S. Lau, Debabrata Mukhopadhyay, Shi Wen Jiang, Brian Patrick O'Neill, Kaustubh Datta, Jinping Li

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) accounts for about 38% of primary brain tumors in the United States. GBM is characterized by extensive angiogenesis induced by vascular growth factors and cytokines. The transcription of these growth factors and cytokines is regulated by the Hypoxia-Inducible-Factor-1(HIF- 1), which is a key regulator mediating the cellular response to hypoxia. It is known that Factor Inhibiting HIF-1, or FIH-1, is also involved in the cellular response to hypoxia and has the capability to physically interact with HIF-1 and block its transcriptional activity under normoxic conditions. Delineation of the regulatory role of FIH-1 will help us to better understand the molecular mechanism responsible for tumor growth and progression and may lead to the design of new therapies targeting cellular pathways in response to hypoxia. Previous studies have shown that the chromosomal region of 10q24 containing the FIH-1 gene is often deleted in GBM, suggesting a role for the FIH-1 in GBM tumorigenesis and progression. In the current study, we found that FIH-1 is able to inhibit HIF-mediated transcription of GLUT1 and VEGF-A, even under hypoxic conditions in human glioblastoma cells. FIH-1 has been found to be more potent in inhibiting HIF function than PTEN. This observation points to the possibility that deletion of 10q23-24 and loss or decreased expression of FIH-1 gene may lead to a constitutive activation of HIF-1 activity, an alteration of HIF-1 targets such as GLUT-1 and VEGF-A, and may contribute to the survival of cancer cells in hypoxia and the development of hypervascularization observed in GBM. Therefore FIH-1 can be potential therapeutic target for the treatment of GBM patients with poor prognosis.

Original languageEnglish (US)
Article numbere86102
JournalPloS one
Volume9
Issue number1
DOIs
StatePublished - Jan 23 2014

Fingerprint

Transcription
Glioblastoma
Vascular Endothelial Growth Factor A
Tumors
hypoxia
Intercellular Signaling Peptides and Proteins
Genes
vascular endothelial growth factor A
Cytokines
Hypoxia-Inducible Factor 1
growth factors
Brain
cytokines
transcription (genetics)
Chemical activation
Cells
therapeutics
neoplasms
normoxia
angiogenesis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Wang, E., Zhang, C., Polavaram, N., Liu, F., Wu, G., Schroeder, M. A., ... Li, J. (2014). The role of Factor Inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. PloS one, 9(1), [e86102]. https://doi.org/10.1371/journal.pone.0086102

The role of Factor Inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. / Wang, Enfeng; Zhang, Chunyang; Polavaram, Navatha; Liu, Fengming; Wu, Gang; Schroeder, Mark A.; Lau, Julie S.; Mukhopadhyay, Debabrata; Jiang, Shi Wen; O'Neill, Brian Patrick; Datta, Kaustubh; Li, Jinping.

In: PloS one, Vol. 9, No. 1, e86102, 23.01.2014.

Research output: Contribution to journalArticle

Wang, E, Zhang, C, Polavaram, N, Liu, F, Wu, G, Schroeder, MA, Lau, JS, Mukhopadhyay, D, Jiang, SW, O'Neill, BP, Datta, K & Li, J 2014, 'The role of Factor Inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme', PloS one, vol. 9, no. 1, e86102. https://doi.org/10.1371/journal.pone.0086102
Wang, Enfeng ; Zhang, Chunyang ; Polavaram, Navatha ; Liu, Fengming ; Wu, Gang ; Schroeder, Mark A. ; Lau, Julie S. ; Mukhopadhyay, Debabrata ; Jiang, Shi Wen ; O'Neill, Brian Patrick ; Datta, Kaustubh ; Li, Jinping. / The role of Factor Inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. In: PloS one. 2014 ; Vol. 9, No. 1.
@article{da87a27db53d4b9f9f54d2d71c00a818,
title = "The role of Factor Inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme",
abstract = "Glioblastoma multiforme (GBM) accounts for about 38{\%} of primary brain tumors in the United States. GBM is characterized by extensive angiogenesis induced by vascular growth factors and cytokines. The transcription of these growth factors and cytokines is regulated by the Hypoxia-Inducible-Factor-1(HIF- 1), which is a key regulator mediating the cellular response to hypoxia. It is known that Factor Inhibiting HIF-1, or FIH-1, is also involved in the cellular response to hypoxia and has the capability to physically interact with HIF-1 and block its transcriptional activity under normoxic conditions. Delineation of the regulatory role of FIH-1 will help us to better understand the molecular mechanism responsible for tumor growth and progression and may lead to the design of new therapies targeting cellular pathways in response to hypoxia. Previous studies have shown that the chromosomal region of 10q24 containing the FIH-1 gene is often deleted in GBM, suggesting a role for the FIH-1 in GBM tumorigenesis and progression. In the current study, we found that FIH-1 is able to inhibit HIF-mediated transcription of GLUT1 and VEGF-A, even under hypoxic conditions in human glioblastoma cells. FIH-1 has been found to be more potent in inhibiting HIF function than PTEN. This observation points to the possibility that deletion of 10q23-24 and loss or decreased expression of FIH-1 gene may lead to a constitutive activation of HIF-1 activity, an alteration of HIF-1 targets such as GLUT-1 and VEGF-A, and may contribute to the survival of cancer cells in hypoxia and the development of hypervascularization observed in GBM. Therefore FIH-1 can be potential therapeutic target for the treatment of GBM patients with poor prognosis.",
author = "Enfeng Wang and Chunyang Zhang and Navatha Polavaram and Fengming Liu and Gang Wu and Schroeder, {Mark A.} and Lau, {Julie S.} and Debabrata Mukhopadhyay and Jiang, {Shi Wen} and O'Neill, {Brian Patrick} and Kaustubh Datta and Jinping Li",
year = "2014",
month = "1",
day = "23",
doi = "10.1371/journal.pone.0086102",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - The role of Factor Inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme

AU - Wang, Enfeng

AU - Zhang, Chunyang

AU - Polavaram, Navatha

AU - Liu, Fengming

AU - Wu, Gang

AU - Schroeder, Mark A.

AU - Lau, Julie S.

AU - Mukhopadhyay, Debabrata

AU - Jiang, Shi Wen

AU - O'Neill, Brian Patrick

AU - Datta, Kaustubh

AU - Li, Jinping

PY - 2014/1/23

Y1 - 2014/1/23

N2 - Glioblastoma multiforme (GBM) accounts for about 38% of primary brain tumors in the United States. GBM is characterized by extensive angiogenesis induced by vascular growth factors and cytokines. The transcription of these growth factors and cytokines is regulated by the Hypoxia-Inducible-Factor-1(HIF- 1), which is a key regulator mediating the cellular response to hypoxia. It is known that Factor Inhibiting HIF-1, or FIH-1, is also involved in the cellular response to hypoxia and has the capability to physically interact with HIF-1 and block its transcriptional activity under normoxic conditions. Delineation of the regulatory role of FIH-1 will help us to better understand the molecular mechanism responsible for tumor growth and progression and may lead to the design of new therapies targeting cellular pathways in response to hypoxia. Previous studies have shown that the chromosomal region of 10q24 containing the FIH-1 gene is often deleted in GBM, suggesting a role for the FIH-1 in GBM tumorigenesis and progression. In the current study, we found that FIH-1 is able to inhibit HIF-mediated transcription of GLUT1 and VEGF-A, even under hypoxic conditions in human glioblastoma cells. FIH-1 has been found to be more potent in inhibiting HIF function than PTEN. This observation points to the possibility that deletion of 10q23-24 and loss or decreased expression of FIH-1 gene may lead to a constitutive activation of HIF-1 activity, an alteration of HIF-1 targets such as GLUT-1 and VEGF-A, and may contribute to the survival of cancer cells in hypoxia and the development of hypervascularization observed in GBM. Therefore FIH-1 can be potential therapeutic target for the treatment of GBM patients with poor prognosis.

AB - Glioblastoma multiforme (GBM) accounts for about 38% of primary brain tumors in the United States. GBM is characterized by extensive angiogenesis induced by vascular growth factors and cytokines. The transcription of these growth factors and cytokines is regulated by the Hypoxia-Inducible-Factor-1(HIF- 1), which is a key regulator mediating the cellular response to hypoxia. It is known that Factor Inhibiting HIF-1, or FIH-1, is also involved in the cellular response to hypoxia and has the capability to physically interact with HIF-1 and block its transcriptional activity under normoxic conditions. Delineation of the regulatory role of FIH-1 will help us to better understand the molecular mechanism responsible for tumor growth and progression and may lead to the design of new therapies targeting cellular pathways in response to hypoxia. Previous studies have shown that the chromosomal region of 10q24 containing the FIH-1 gene is often deleted in GBM, suggesting a role for the FIH-1 in GBM tumorigenesis and progression. In the current study, we found that FIH-1 is able to inhibit HIF-mediated transcription of GLUT1 and VEGF-A, even under hypoxic conditions in human glioblastoma cells. FIH-1 has been found to be more potent in inhibiting HIF function than PTEN. This observation points to the possibility that deletion of 10q23-24 and loss or decreased expression of FIH-1 gene may lead to a constitutive activation of HIF-1 activity, an alteration of HIF-1 targets such as GLUT-1 and VEGF-A, and may contribute to the survival of cancer cells in hypoxia and the development of hypervascularization observed in GBM. Therefore FIH-1 can be potential therapeutic target for the treatment of GBM patients with poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84899874531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899874531&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0086102

DO - 10.1371/journal.pone.0086102

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e86102

ER -